However, less than 10% of PDAC patients harbor an actionable somatic or germline biomarker, including microsatellite stability high (MSI-H), high tumor mutational burden (TMB), BRCA1/2, BRAF V600E, KRAS G12C, HER2, or activating fusions, generally observed in KRAS wild type tumors (8–11). The gene discussed is KRAS; the disease is neoplasm.